Longitudinal healthcare claims databases are frequently used for studying the comparative safety and effectiveness of medications, but results from these studies may be biased due to residual confounding. It is unclear whether methods for confounding adjustment that have been shown to perform well in small, simple nonrandomized studies are applicable to the large, complex pharmacoepidemiologic studies created from secondary healthcare data. Ordinary simulation approaches for evaluating the performance of statistical methods do not capture important features of healthcare claims. In this paper, we develop and validate a statistical framework for creating replicated simulation datasets from an empirical cohort study in electronic healthcare claims data. Our approach relies on reusing the observed covariate and exposure data without modification in all simulated datasets to preserve the associations among these variables. Repeated outcomes are simulated using a true treatment effect of the investigator's choice and the baseline hazard function estimated from the empirical data. As an example, we applied our framework to a study of high versus low-intensity statin use and cardiovascular outcomes. Simulated data was based on real data drawn from Medicare Parts A and B linked with a prescription drug insurance claims database maintained by Caremark. We compared properties of the data simulated using this framework with the empirical data on which the simulations were based. In addition, we used the simulated datasets to compare variable selection strategies for confounder adjustment via the propensity score, including high-dimensional approaches that could not be evaluated with ordinary simulation methods. We found that our simulation ramework created datasets that closely resembled the observed complex data tructure, b f s ut had the advantage of an investigator-specified exposure effect.
Introduction
Longitudinal healthcare claims databases are frequently used for studying the comparative safety and effectiveness of medications. Administrative healthcare data generally provide a longitudinal record of medical services, procedures, diagnoses, and medications for large numbers of patients, and therefore provide a rich data source for conducting pharmacoepidemiologic research. Compared with randomized trials, the data available in healthcare claims better represent the full spectrum of patients that are exposed to a drug and the processes of care in routine practice (Schneeweiss and Avorn, 2005; Strom and Carson, 1990) . However, drug studies in claims data may suffer from bias due to residual confounding (Brookhart et al., 2010) , and it is unclear whether methods for confounding adjustment that have been shown to perform well in small, simple nonrandomized studies are applicable to the cohort studies created from complex healthcare claims data.
Monte Carlo simulation can be used to evaluate the performance of causal inference methods, but ordinary simulation approaches do not capture important features of healthcare claims. For example, healthcare claims databases often have hundreds, or even thousands, of measured covariates with complex covariance structures. These covariates, either singly or in combination, may serve as proxies for unmeasured confounders and be effectively used to remove bias (Schneeweiss et al., 2009 ). Further, the complexity of real-world data extends beyond confounding; patients' follow-up time and censoring patterns are often associated with exposure and outcome via a path of underlying characteristics. These complexities cannot be replicated in fully synthetic simulated data, as they are generally not completely understood and vary by data source.
As an alternative to simulation, Vaughan et al. (Vaughan et al., 2009) suggested creating "plasmode" datasets. A plasmode is a real dataset that is created from natural processes but has some aspect of the data-generating model known, for example, a "spike-in" experiment in microarray analysis of gene expression where a known amount of genome transcript is added to each sample. Merging this concept with simulation techniques has led to several studies of methods performance that use real observed data augmented with simulated data (Elobeid et al., 2009; Gadbury et al., 2008) . Other approaches utilize fully simulated data, but create associations among variables to match estimated associations from observed data (Chao et al., 2010; Erenay et al., 2011; McClure et al., 2008; Rolka et al., 2005; Schmidt et al., 2009) , including one approach specifically designed for simulating an entire healthcare claims database (Murray et al., 2011) . However, due to the massive size and complexity of the data in this approach, generally only one dataset is created for each set of simulation parameters, and the relative contributions of bias and variance to estimation error cannot be judged.
In this paper, we outline a statistical and computational framework for creating replicated simulation datasets based on an empirical pharmacoepidemiologic cohort study in healthcare claims data. The objective of this work is to enable the evaluation of analysis approaches in simulated data that preserve the complex features and information content of claims data but also have a known true treatment effect. As an example, we applied our framework to a study of high versus low-intensity statin use and cardiovascular outcomes. Simulated data was based on real data drawn from Medicare Parts A and B linked with a prescription drug insurance claims database maintained by Caremark. We compared properties of the data simulated using this framework with the empirical data on which the simulations were based. In addition, we used the simulated datasets to compare variable selection strategies for confounder adjustment via the propensity score, including high-dimensional approaches that could not be evaluated with ordinary simulation methods since their performance depends on the information richness and complexity of the underlying empirical data source.
Methods
Our simulation approach relies on reusing the observed covariate and exposure data without modification in all simulated datasets to preserve the empirical associations among these variables. Repeated outcomes are simulated using a true treatment effect of the investigator's choice and the baseline hazard function estimated from the empirical data ( Figure 1 ). R code and documentation for the simulation setup are available in the Web Appendix.
Construct the cohort
The first task in creating simulated datasets is to create the cohort on which the simulations will be based from the larger healthcare database. The specifics of the study design, including inclusion and exclusion criteria for the cohort, definitions of exposures and covariates, and determinations of follow-up and censoring for outcome events, are important in determining the performance of any statistical methods subsequently applied to the data. As these issues are not the focus of this paper, we refer the reader to the wide array of literature on the subject for specific information on these determinations. In general, we recommend a "new user design" with an active comparator (Ray, 2003; Schneeweiss, 2010) , where two treatments with similar clinical indications are compared in patients initiating one treatment or the other with no history of use in the prior six months (or some other pre-specified period). Covariates (diagnoses, medications, and health system service use) are assessed in the period preceding initiation of treatment, and assessment of outcomes begins on or after the date of treatment initiation.
The result of this design is a dataset where each patient has information on exposure ( indicates initiating one treatment, indicates initiating the reference treatment), presence of an outcome event (Y), and length of follow-up time (T). In addition, we assume that there is a large pool of potential covariates, C, that contains potentially hundreds or thousands of distinct codes for diagnoses, procedures, hospitalizations, medications and other health system service use in the period preceding treatment initiation (Schneeweiss et al., 2009) . This dataset provides all of the information that we will use for constructing the simulated datasets. 5
Select covariates for simulation basis
Within the hundreds or thousands of potential covariates in C, we identify a subset to be used for outcome generation. We recommend specifying a set of covariates that are believed to be associated with the outcome, including important demographic information such as age, gender, and race. We refer to this subset as C 1 , and we refer to the complement (everything in C not included in C 1 ) as C 0 . The variables in C 1 are used for simulating outcome variables. In general, including more covariates in C 1 will result in more realistic simulated outcomes, as any associations between covariates and outcome present in the observed data will be lost if those covariates are not included in C 1 . However, including all potential covariates in C 1 will generally be infeasible due to the model estimation required in subsequent steps. If any of the variables in C 1 are associated with exposure, or if they are associated with other measured covariates that are correlates of exposure, then confounding will be present in the simulated datasets.
Estimate associations with outcome and censoring
In order to produce outcome and censoring times that have realistic associations with covariates, we estimate the empirical multivariate associations with two Cox proportional hazards models. In the first model, we estimate the hazard of the outcome event in the observed data. We use penalized splines (Eilers and Marx, 1996; Hurvich et al., 1998) for estimating the effect of continuous covariates (e.g., age, number of comorbid conditions) as smooth nonlinear functions and ridge regression for estimating the effect of binary variables (including the exposure), so that extreme and imprecise parameter estimates on covariates with low prevalence are shrunk toward a more reasonable null value (Gray, 1992; Therneau and Grambsch, 2000; Therneau et al., 2003) . Each of these estimation techniques is implemented in the survival package in R (Therneau, 2011) and allow for precise estimation even when many predictors are included in the model. The second model is identical except that we estimate the hazard of censoring, represented in the model as the reverse of the outcome variable ( ).
Predict survival and censoring
To translate the empirical associations into the simulated outcome data, we use the fitted models from the previous step to predict each patient's expected survival and censoring time given his C 1 values. We extract the Breslow estimates (Breslow, 1975) of the baseline event-free survival function, , and the baseline censoring-free survival function, . In addition, we extract the vector of estimated coefficients from each model ( and for the event and censoring models, respectively). The desired true effects are specified by selectively replacing the values in with desired values at this step. For example, an alternative true effect of exposure can be inserted by replacing the estimated coefficient on X with another value. In addition, one may increase the overall amount of confounding by replacing the covariate coefficients in with larger values.
We denote the coefficient vector used for event time simulation as . This vector now defines the true causal effects of X and C 1 on the simulated outcomes.
A predicted event-free survival curve for each individual is then calculated as:
where D is the design matrix from the estimated time to event model. A predicted censor-free survival curve is calculated similarly using and with the exception that the predicted censor-free survival curve is set to zero on the date of administrative censoring if present. 7
2.4.1
If any values in
Adjust the baseline survival
are replaced in this step in , then the overall event rate in the subsequent simulated data will be different from that observed in the empirical data. In order to keep the overall event rate the same (or to specify another preferred event rate) in the simulated data, we adjust the baseline event-free survival function.
Specifically, in order to guarantee that the probability of having an event in the period defined by T=t is approximately p, we find the value of such that This value of is then applied to the predicted survival function for each individual in subsequent steps. 8
Simulate outcomes
We now simulate survival and censoring times for each patient using the predicted event-free and censor-free survival curves constructed above. We use the fact that for any arbitrary distribution defined by the cumulative distribution function F, the distribution of is given by F, where R is a random uniform variable in (0,1) (Casella and Berger, 2001 
Analyze simulated data
We now have an exposure vector X, a large collection of potential covariates C, and J vectors of event indicators and follow-up times . Furthermore, we have created the outcomes in such a way that the complete data generating mechanism for the outcome is known, including the effect sizes for exposure and all covariates. The data generating mechanism for X and C remain unknown, as these data remain unaltered from their observed values, and any associations that exist among these variables in the observed data remain intact.
If desired, unobserved confounding can be created at this step by setting aside a subset of the predictors of outcome C 1 to be the unobserved confounders U, so that the variables available for analysis are . By hiding the variables in U from the confounder adjustment methods applied to the simulated data, we may observe the performance of methods under known unobserved confounding. By varying which covariates are set aside and their strength of association with outcome, we can vary the strength of the unobserved confounding in the simulations.
Analyzing these data, we return an estimate of exposure effect for each of the J simulated outcomes, . Using these estimates, we may calculate features of the estimation procedure as in ordinary simulation studies, for example bias and variance.
However, because we have only one set of exposures and covariates, rather than one for each simulation dataset, the variability of estimates across the repeated samples will not fully reflect the true sampling variability of the data, but only the residual variability of the outcome.
Application

Source cohort and simulation
We applied our framework to a cohort study of high-intensity versus low-intensity statin medications for the prevention of cardiovascular events. These data come from a cohort Using these covariates, we simulated 100 datasets with a true high versus lowintensity treatment effect hazard ratio of 1.0 and the effects of all other predictors set at their estimated values (scenario 1). In order to keep the total number of events approximately the same as in the observed data, we adjusted the baseline hazard function. We simulated a second set of 100 datasets with a true high versus lowintensity hazard ratio of 1.5 and the coefficients on all other predictors set at 2 times their estimated value (scenario 2). In this case, we increased the baseline hazard to ensure approximately 5% of patients would have an event within 180 days.
Comparison of simulated and observed data
To ensure that our simulation strategy was producing realistic data that closely matched the observed data, we compared the observed and simulated outcome vectors via graphical displays. In Figure 2 , we present density plots for censoring times (top panel) and event times (bottom panel). The densities from the observed data are plotted in black and the densities from each of the 100 simulated datasets are plotted in gray and red for scenarios 1 and 2, respectively. These plots show that the distribution of event times and censoring times were very similar for observed and simulated data, particularly in scenario 1. In scenario 2, the overall number of events was increased, causing a slightly larger proportion of patients to have an event early during follow-up and a slightly smaller proportion of patients to be censored at 180 days of follow-up. Figure 3 shows the proportion of patients with an event in each of five patient subgroups: 1) females, 2) males, 3) patients with a history of MI or ACS in the preexposure period (post-coronary), 4) patients with a history of diabetes mellitus (DM) in the pre-exposure period, and 5) patients with a history of rheumatoid arthritis (RA) in the pre-exposure period. These subgroups were chosen to show patient outcomes in the general population (males and females) as well as in subgroups with risk factors for cardiovascular events (post-coronary, DM, RA). The proportions in the observed data are shown with a solid green point and the distributions of proportions across the 100 simulated datasets are shown with black and red boxplots, separately for scenario 1 and scenario 2, respectively. Again, the data from scenario 1 closely resembled the observed data with some random variation. The proportions calculated from the simulated data in scenario 2 were higher than the observed proportions as expected, but followed similar patterns.
Evaluating variable selection strategies in simulated data
Using the simulated data from scenario 2, we compared strategies for selecting variables to include in the PS. The primary purpose of this study is to evaluate the performance of high-dimensional PS (hdPS) variable selection approaches frequently used in pharmacoepidemiology for identifying important confounders among the thousands of potential covariates in longitudinal claims data with little investigator input Schneeweiss et al., 2009) . In "exposure-based hdPS," variables are selected based on their association with exposure only. In "bias-based hdPS," variables are selected based on their associations with both exposure and outcome. See the references above for additional details. In empirical studies, hdPS algorithms have been shown to perform well by reproducing results observed in randomized trials, but they have not been studied via simulation.
Using the simulated data from Scenario 2, we compared hdPS algorithms with correctly-specified outcome and PS models. Specifically, in each simulated dataset we estimated the effect of high versus low-intensity statins using several Cox proportional hazards models. We estimated 1) a "crude" model that only included a term for the exposure, 2) a model with terms for exposure, patient age, sex, and year of statin initiation (the A/S/Y model), and 3) a model that included exposure and linear terms for all covariates in C 1 (the all variables model). In addition, we estimated 3 PS-adjusted models, including 1) exposure-based hdPS, 2) bias-based hdPS, and 3) a PS model that included linear terms for all covariates in C 1 (the all variables PS model). In each of the PS-adjusted Cox models, we included terms for exposure, age, sex, year, and indicators of PS decile. Therefore, we estimated 6 outcome models (and 6 exposure effects) in each simulated dataset.
The results from this study are plotted in Figure 4 . This figure displays boxplots for the distributions of exposure effect estimates across simulated datasets from each of the 6 outcome models. As expected, the estimates from the crude model that did not adjust for confounding was positively biased for the true hazard ratio of 1.5. Adjusting for age, sex, and year had essentially no effect, but adjusting for all variables in the outcome model yielded a median effect estimate nearly identical to the truth (median 1.50, 95%
Monte Carlo interval 0.96-2.07). When adjusting for deciles of the all variables PS, the exposure effect estimators were slightly biased, probably due to residual covariate imbalances within strata, but were still very close to the true exposure effect (median 1.45, 95% interval 0.96-1.95). Almost identical results were achieved when adjusting for the PS constructed using the bias-based hdPS algorithm. The exposure effect estimator that adjusts for the exposure-based hdPS was slightly more biased than the other two PS stratified estimators, but still had a median reduction in bias of 67% from the crude bias.
When interpreting the variation of exposure effect estimates, it is important to recall that the exposure and covariate data were identical in each simulated dataset. Only the follow-up time and event status changed from one dataset to the next. Therefore, the all-variables PS and the exposure-based hdPS did not change across simulated datasets.
However, the selection of variables included in the bias-based hdPS was different in each simulated dataset because this covariate selection depends on the outcome. Thus, the variation in the bias-based hdPS exposure effect estimates incorporated the uncertainty induced by the selection process (at least the portion that can be attributed to the outcome), while the estimates from the other two PS models did not. Figure 4 shows that adjusting for deciles of the all-variables PS was slightly more efficient than adjusting for the variables directly in the outcome model. The bias-based hdPS estimator was even more precise, while the exposure-based hdPS estimator resulted in much less variability than all other adjustment methods, although this was likely due to the repeated use of the same PS across simulated datasets.
These results indicate that, in this scenario, hdPS algorithms performed as well or nearly as well as an investigator-specified PS model that included all covariates used to generate the outcome. However, the hdPS algorithms were completely automated and required effectively no investigator input into the choice of covariates. By contrast, the correctly-specified PS model required detailed knowledge and investigator specification of all 61 covariates included. Given that complete knowledge of prognostic covariates for outcome is rarely (if ever) available, hdPS algorithms may be very useful for identifying covariates to include in the PS model in longitudinal claims data.
Discussion
In this paper, we have outlined steps for creating simulated cohort studies based on observed data from healthcare claims. We applied our simulation framework to a typical pharmacoepidemiologic study and compared the simulated outcome data to the observed outcomes. In addition, we provided an example of how this simulation framework can be used to evaluate statistical methods that were previously not able to be evaluated in simulated data. We found that our simulation framework created datasets that closely resembled the observed complex data structure, but had the advantage of an investigator-specified event rate and exposure effect.
The validity of our framework is further reinforced when considering the results of our example simulation study in the context of other literature on covariate selection.
The reduction in bias using bias-based hdPS over exposure-based hdPS was expected, since past studies have shown that adjusting for variables that influence exposure but have minimal effect on the outcome can amplify residual confounding bias (Myers et al., 2011; Pearl, 2010; Pearl, 2011) . It seems probable that the bias-based hdPS algorithm avoids selecting such covariates by considering associations with outcome in the selection procedure. When adjusting for strata of the PS, past theoretical results have shown that using the estimated PS, rather than a true PS, will generally result in reduced variability in the exposure effect estimator, particularly if covariates that strongly predict outcome but are only weakly associated with exposure are included in the PS (Williamson et al., 2012) . This reduced variability is a result of the estimated PS adjusting for chance imbalances in covariates that are associated with outcome but may not be structurally related to the treatment decision. Both hdPS algorithms select a larger number of covariates than the pre-defined PS and therefore are likely to account for more chance imbalances and result in the observed increased precision for those methods. Finally, the reduced variation in the all-variables PS approach compared with the all-variables outcome model approach aligns with prior simulation studies that show that in the case of few events and many covariates, adjusting for the PS is more efficient than adjusting for the variables directly in the outcome model (Cepeda et al., 2003) .
Although our framework was ideal for evaluating the hdPS algorithms, which rely on a large pool of pre-exposure healthcare claims from which to select covariates, the simulation procedure has some limitations that may lessen its utility in evaluating other methods. First, comparing the variability of exposure effect estimators is complicated by the fact that exposure and covariate data is not regenerated in each simulated dataset. Given that repeated simulations are intended to mimic the variation from random sampling, this method will generally produce data that underrepresent the true variability of statistical approaches applied to it. Second, in our simulation framework, outcomes are generated based on a limited number of investigator-defined covariates, while in observed data, outcomes may be influenced by a much larger set of factors, both measured and unmeasured. However, because the covariate data and associations among covariates remain intact in our simulation framework, many covariates may influence outcome indirectly via their association with variables in C 1 , in addition to the variables that are used for directly generating outcome. In addition, our simulation framework provides the ability to set aside some covariates from C 1 to be "unmeasured," thereby mimicking this aspect of real-world claims data. Therefore, despite these limitations, the simulation framework presented in this paper can be useful for evaluating methods for comparative safety and effectiveness analyses in data that mimic the complex structure of observed healthcare claims. Figure 1: Diagram showing the steps in the simulation framework. Dashed lines represent carrying a data element unchanged from one step to the next. Solid arrows represent using a data element to create new data structures. The end result is a sequence of exposure effect estimates (one for each of J simulated datasets) given by . Covariates: C is all measured, C 1 is pre-defin e d , C 0 is all others, C* is all measured except those from C 1 set aside in U to be unmeasured 
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